These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11351308)

  • 21. [Soluble expression of recombinant immunotoxin against human bladder carcinoma and its anti-tumor activity].
    Chao K; He D; Yang H; Zhang Z; Lin Q; Guo AG; Huang HL
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Sep; 20(5):568-71. PubMed ID: 15367349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3.
    Benhar I; Pastan I
    J Biol Chem; 1995 Oct; 270(40):23373-80. PubMed ID: 7559495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.
    Hexham JM; Dudas D; Hugo R; Thompson J; King V; Dowling C; Neville DM; Digan ME; Lake P
    Mol Immunol; 2001 Sep; 38(5):397-408. PubMed ID: 11684296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning.
    Klimka A; Matthey B; Roovers RC; Barth S; Arends JW; Engert A; Hoogenboom HR
    Br J Cancer; 2000 Jul; 83(2):252-60. PubMed ID: 10901379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
    Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
    J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.
    Schmidt M; McWatters A; White RA; Groner B; Wels W; Fan Z; Bast RC
    Gynecol Oncol; 2001 Feb; 80(2):145-55. PubMed ID: 11161852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
    Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
    Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A.
    Onda M; Olafsen T; Tsutsumi Y; Bruland OS; Pastan I
    J Immunother; 2001; 24(2):144-50. PubMed ID: 11265772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.
    Theuer CP; Kreitman RJ; FitzGerald DJ; Pastan I
    Cancer Res; 1993 Jan; 53(2):340-7. PubMed ID: 8417828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
    Onda M; Nagata S; Tsutsumi Y; Vincent JJ; Wang Q; Kreitman RJ; Lee B; Pastan I
    Cancer Res; 2001 Jul; 61(13):5070-7. PubMed ID: 11431343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma.
    Kreitman RJ; Bailon P; Chaudhary VK; FitzGerald DJ; Pastan I
    Blood; 1994 Jan; 83(2):426-34. PubMed ID: 8286741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
    Barth S; Huhn M; Wels W; Diehl V; Engert A
    Int J Mol Med; 1998 Jan; 1(1):249-56. PubMed ID: 9852227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.
    Onda M; Beers R; Xiang L; Lee B; Weldon JE; Kreitman RJ; Pastan I
    Proc Natl Acad Sci U S A; 2011 Apr; 108(14):5742-7. PubMed ID: 21436054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
    Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
    Blood; 2000 Jun; 95(12):3909-14. PubMed ID: 10845927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines.
    Tur MK; Sasse S; Stöcker M; Djabelkhir K; Huhn M; Matthey B; Gottstein C; Pfitzner T; Engert A; Barth S
    Int J Mol Med; 2001 Nov; 8(5):579-84. PubMed ID: 11605031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of single-chain antibody (sFv)-toxin fusion proteins produced in vitro in rabbit reticulocyte lysate.
    Nicholls PJ; Johnson VG; Andrew SM; Hoogenboom HR; Raus JC; Youle RJ
    J Biol Chem; 1993 Mar; 268(7):5302-8. PubMed ID: 8444903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses.
    Kreitman RJ; Pastan I
    Cancer Res; 1998 Mar; 58(5):968-75. PubMed ID: 9500458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors.
    Singh R; Samant U; Hyland S; Chaudhari PR; Wels WS; Bandyopadhyay D
    Mol Cancer Ther; 2007 Feb; 6(2):562-9. PubMed ID: 17308054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Studies of the expression, purification, renaturation and biologic activity of an anti-CEA immunotoxin].
    Yang H; He D; Chao K; Lin Q; You S; Huang HL
    Sheng Wu Gong Cheng Xue Bao; 2004 May; 20(3):348-51. PubMed ID: 15971603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
    Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
    J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.